Onasemnogene abeparvovec, marketed as Zolgensma, is a one-time gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients with bi-allelic mutations in the SMN1 gene. Developed by Novartis Gene Therapies, it delivers a functional copy of the SMN1 gene using an adeno-associated virus serotyp...Read More »
November 25, 2025
Inotuzumab ozogamicin, marketed as Besponsa by Pfizer, is an antibody-drug conjugate designed for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The therapy received regulatory approvals in the United States and Europe in 2017 and has since...Read More »
November 25, 2025
The Product × Indication cross-segment analysis of the compression therapy & hosiery market shows a strong alignment between advanced product designs and the rising clinical demand for effective edema and venous disorder management. Graduated compression stockings, compression bandages, ...Read More »
November 25, 2025
Fluticasone (Flovent) is an inhaled corticosteroid used globally as a long-term controller therapy for asthma, available in both metered-dose (HFA) and dry-powder (Diskus) inhaler forms. Although branded Flovent was discontinued in the United States in 2024, generic fluticasone remains widely used...Read More »
November 25, 2025
Evinacumab (Evkeeza), developed by Regeneron Pharmaceuticals and commercialized globally with Ultragenyx, is a first-in-class ANGPTL3 inhibitor transforming the treatment of Homozygous Familial Hypercholesterolemia (HoFH). By uniquely lowering LDL-C even in patients with severely impaired LDL rece...Read More »
November 25, 2025
Germany’s dietary supplements retail sector is adapting rapidly to evolving consumer behavior, characterized by growing interest in preventive wellness, natural formulas and convenience. Traditional pharmacies continue to play a pivotal role because German consumers frequently associate supp...Read More »
November 25, 2025
Icosapent Ethyl (Vascepa), developed by Amarin, has redefined cardiovascular risk management through its highly purified EPA-only formulation and its strong clinical evidence demonstrating meaningful reductions in major adverse cardiovascular events among statin-treated patients with elevated trig...Read More »
November 24, 2025
The Europe hair loss supplements market size was estimated at USD 1.25 billion in 2024 and is projected to reach USD 2.05 billion by 2033, growing at a CAGR of 6.8% from 2025 to 2033. The Europe Hair Loss Supplements market is experiencing dynamic growth, propelled by changing consumer preferences...Read More »
November 24, 2025
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist used in type 2 diabetes management and for lowering cardiovascular risk in patients with underlying conditions. It supports glycemic control, weight management, and cardiovascular protection, while weekly dosing improves treatment adh...Read More »
November 20, 2025
The Europe vitamin D supplements market continues to demonstrate consistent growth, supported by aging population, increased health awareness, and a growing consumer shift towards wellness. This rise in demand reflects the broader trend of consumers proactively seeking to improve their health thro...Read More »
November 19, 2025
Breztri Aerosphere, a combination of Budesonide, Glycopyrrolate, and Formoterol Fumarate, developed and marketed by AstraZeneca, has become a prominent treatment option for chronic obstructive pulmonary disease (COPD) and asthma. The therapy’s unique triple-action mechanism incorporating a c...Read More »
November 18, 2025
The enzyme indicators represent a cutting-edge advancement in sterilization monitoring, offering rapid and precise validation of sterilization processes. Enzyme indicators offer a safer, faster, and smarter method for bio-decontamination validation, enabling optimized cycle design, reducing the ri...Read More »
November 18, 2025
Relugolix Combo (Myfembree/Ryeqo), developed by Myovant Sciences now part of Sumitomo Pharma and co-commercialized with Pfizer Inc., is an oral, once-daily GnRH receptor antagonist combination indicated for uterine fibroids and endometriosis-associated pain. The therapy combines relugolix, estradi...Read More »
November 18, 2025
Elagolix (Orilissa), developed by AbbVie Inc., represents a major advancement in women’s health as the first oral gonadotropin-releasing hormone (GnRH) antagonist approved for the management of endometriosis-associated pain and uterine fibroids. Designed to provide dose-dependent estrogen su...Read More »
November 18, 2025
Bimekizumab (Bimzelx), developed by UCB, is emerging as a highly differentiated biologic in the global immunology market through its unique dual inhibition of IL-17A and IL-17F, delivering rapid, deep, and sustained clinical responses that surpass many existing IL-17 therapies. Since securing FDA ...Read More »
November 17, 2025
Liraglutide (Victoza), developed by Novo Nordisk, is a pioneering GLP-1 receptor agonist that has reshaped the management of type 2 diabetes and obesity through its proven efficacy in glycemic control, weight reduction, and cardiovascular risk reduction. Victoza and Saxenda both contain liraglutid...Read More »
November 14, 2025
The Goserelin (Zoladex) market continues to evolve, supported by its established role in hormone-dependent cancers and expanding global access to generic formulations. Demand is primarily driven by its clinical utility in prostate cancer, breast cancer, and gynecologic indications, along with sust...Read More »
November 12, 2025
The Triptorelin (Trelstar) market is advancing as a key segment within hormone-regulating therapeutics, supported by its long-established role in prostate cancer treatment and expanding use in central precocious puberty (CPP) and assisted reproductive technologies (ART). The market continues to sh...Read More »
November 12, 2025
The cell culture industry is undergoing a competitive reshaping driven by the advance of cell and gene therapies, deeper adoption of chemically defined specialty formulations, and increasing emphasis on regulatory-grade traceability. While traditional cell lines and classical media remain foundati...Read More »
November 11, 2025
The U.S. independent pharmacies market size was valued at USD 172.56 billion in 2024 and is expected to expand at a CAGR of 4.26% from 2025 to 2033. The study covers more than 11,000 independent pharmacies at state level which helps to understand details regarding their location, address, ownershi...Read More »
November 11, 2025